Stock Research: Champions Oncology

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

Champions Oncology

NAQ:CSBR US15870P3073
52
  • Value
    4
  • Growth
    13
  • Safety
    Safety
    89
  • Combined
    13
  • Sentiment
    99
  • 360° View
    360° View
    52
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Champions Oncology, Inc. is a preclinical and clinical research services provider specializing in oncology drug development. The company offers advanced technology solutions and products for personalized oncology drug development. It operates in the biotechnology and pharmaceutical industries. In the last fiscal year, the company had a market cap of $108 million, profits of $21 million, and revenue of $50 million, with 210 employees.

more
Index
NASDAQ
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 2-Feb-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
4 10 42 37
Growth
13 97 25 61
Safety
Safety
89 1 100 100
Sentiment
99 72 18 25
360° View
360° View
52 54 11 31
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
67 71 3 31
Opinions Change
50 50 95 9
Pro Holdings
n/a 58 1 43
Market Pulse
94 52 55 94
Sentiment
99 72 18 25
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
4 10 42 37
Growth
13 97 25 61
Safety Safety
89 1 100 100
Combined
13 14 23 23
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
79 64 87 93
Price vs. Earnings (P/E)
8 23 1 24
Price vs. Book (P/B)
2 1 1 1
Dividend Yield
1 1 1 1
Value
4 10 42 37
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
71 63 48 43
Profit Growth
6 98 21 98
Capital Growth
9 34 25 29
Stock Returns
31 91 61 43
Growth
13 97 25 61
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
70 46 100 100
Refinancing
17 6 1 7
Liquidity
98 8 80 80
Safety Safety
89 1 100 100

Similar Stocks

Discover high‑ranked alternatives to Champions Oncology and broaden your portfolio horizons.

Salesforce

NYQ:CRM
Country: USA
Industry: Application Software
Size: XX-Large
Full Stock Analysis

Micron

NSQ:MU
Country: USA
Industry: Semiconductors
Size: XX-Large
Full Stock Analysis

Walt Disney

NYQ:DIS
Country: USA
Industry: Movies & Entertainment
Size: XX-Large
Full Stock Analysis

Cognizant Technology

NSQ:CTSH
Country: USA
Industry: IT Consulting & oth. Services
Size: X-Large
Full Stock Analysis

Frequently Asked
Questions

The value case is weak (expensive and low Growth Rank), but sentiment is strong and financing is safe. This scenario may indicate future growth not yet in current financials. This is a speculative choice for investors with a high-risk appetite who are betting on the positive sentiment and safe financing to sustain a long-term turnaround.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing: